Join us for a clinical webinar on US BioTek's newly expanded Organic Acids Profile, designed for naturopathic, functional medicine, and integrative practitioners who want a deeper, more actionable window into their patients' metabolic health. In this webinar, Jacqui Evans, CCN walks through the full scope of the updated test, now featuring over 120 markers analyzed from a single liquid urine sample using LC-MS/MS technology. We break down what organic acids testing reveals about root-cause dysfunction across key physiological systems — including mitochondrial energy production, gut microbiome balance, neurotransmitter metabolism, detoxification capacity, and nutritional status — and how this comprehensive metabolic snapshot translates directly into targeted clinical decisions.
We cover the 60 additional markers added to the expanded profile, explain how they deepen clinical insight across categories like oxidative stress, tryptophan-kynurenine pathway activity, environmental and xenobiotic exposure, oxalate metabolism, and adrenal stress, and show you exactly how to apply these results in your practice. You will also learn how to use the updated dynamic report to communicate findings clearly and confidently with your patients, turning complex biochemical data into a story they can understand and act on.
Key Takeaways:
- See the full picture of your patients' core metabolic function through urinary organic acids that reflect real-time activity across the Krebs cycle, fatty acid oxidation, gut dysbiosis, methylation cofactors, and neurotransmitter breakdown — all from a single liquid urine collection.
- Gain 60 new markers spanning oxidative stress, environmental toxin exposure, and neuroinflammation, including the full tryptophan-kynurenine pathway with actionable ratios like Kynurenic/Quinolinic and Quinolinic Acid/5-HIAA to support mood disorder and chronic inflammation assessment.
- Communicate results clearly and confidently with every patient using the updated dynamic report's plain-language explanations, visual range indicators, and pathway-level context to turn complex data into personalized, actionable treatment plans.
